This clinical trial is seeking 160 participant and is now actively recruiting. The study is seeking participants with mild cognitive impairment and Alzheimer's disease.
Recently, there has been a lot of focus on biomarkers and the possibility of treatments for Alzheimer's disease. If you have seen the use of fMri and how this relates to neural activity and loss of memory, you know that this is exciting research.
Detailed Description:
The development of biomarkers is now especially critical, as there are a number of promising disease-modifying therapies entering early phase clinical trials, with additional novel therapeutic strategies in development. It is essential to develop biomarkers that can detect a "signal of efficacy" over a relatively short time frame for use in Phase II trials.
Ideally biomarkers are needed that can reliably detect the earliest brain alterations due to Alzheimer's Disease pathology, perhaps at a point when there is synaptic dysfunction but not yet widespread neuronal loss.
Functional neuroimaging, in particular functional MRI (fMRI), has significant potential, having already shown promise in detecting regionally specific pharmacological effects on memory related neural activity, and as a sensitive marker of very early cognitive impairment.
This study, a parallel ancillary study of the Alzheimer's Disease Neuroimaging Initiative (ADNI), will first examine reproducibility of fMRI activation, using a face-name associative memory paradigm, and then the alterations in memory-related activation that occur over the course of MCI and mild AD.
The study will also examine the relationship of fMRI activation to clinical variables, memory task performance, genotype, and other imaging techniques cross-sectionally and longitudinally, sampling at multiple time points over a 3-year period.
So far, the only announced locations are in the Boston area. The research is being sponsored by the National Institute on Aging (NIA).
For all the details follow the link --
Evolution of Memory Related ActivitySubscribe to The Alzheimer's Reading Room--via Email
 Bob DeMarco is an Alzheimer's caregiver and editor of the Alzheimer's Reading Room. The Alzheimer's Reading Room is the number one website on the Internet for insight into Alzheimer's disease. Bob taught at the University of Georgia, was an executive at Bear Stearns, the CEO of IP Group, and is a mentor. He has written more than 600 articles with more than 11,000 links on the Internet. Bob resides in Delray Beach, FL. |
More from the Alzheimer's Reading Room
Recently, there has been a lot of focus on biomarkers and the possibility of treatments for Alzheimer's disease. If you have seen the use of fMri and how this relates to neural activity and loss of memory, you know that this is exciting research. So far, the only announced locations are in the Boston area. The research is being sponsored by the National Institute on Aging (NIA).
For all the details follow the link -- Evolution of Memory Related Activity
More from the Alzheimer's Reading Room